LRRK2 and Parkinson disease: DNM3 may be a useful target for the therapy of age-related neurodegenerative diseases, as studies have revealed that genetic variability in DNM3 alters the age of onset for LRRK2 Gly2019Ser Parkinsonism and informs disease-relevant translational neuroscience29.